Nuvation Bio’s safusidenib gets FDA Fast Track, but Phase 3 SIGMA remains the decisive test
FDA Fast Track designation could increase regulatory interaction around safusidenib while Nuvation Bio tests the IDH1 inhibitor across several glioma settings.